Eli Lilly's new diabetes drug continues to show promise as an obesity treatment
Eli Lilly continues to work on commercializing its strong innovation pipeline, which is a key reason the CNBC Investing Club owns the stock.
Konoly
0
41
The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.
Mike Blake | Reuters
